HACEK Group Infections

Back

Background

The acronym HACEK refers to a group of fastidious gram-negative coccobacillary organisms. (Haemophilus species; Actinobacillusactinomycetemcomitans [In 2006 the genus was renamed Aggregatibacter actinomycetemcomitans]; Cardiobacterium hominisEikenella corrodens; and Kingella kingae).[1] HACEK microorganisms grow slowly in standard blood culture media, and recovery may require prolonged incubation. 

Identification can be performed by automated systems but performance may be suboptimal. As with many other organisms, MALDI-TOF is emerging as as potential identification technique for the HACEK group.

HACEK organisms typically are oropharyngeal commensals and have long been recognized as a cause of infective endocarditis (IE).[2, 1]  Eikenella and Cardiobacterium species have been recovered from the gastrointestinal tract and female genital tract.[3] In addition to infective endocarditis, these organisms have been known to cause wound infections (particularly of bite wounds), soft-tissue abscess, brain abscess, endophthalmitis, parotitis, periodontitis, empyema and bacteremia without endocarditis, and osteomyelitis. In addition, rare cases of endometritis and urinary tract infection have been identified. Invasive infections commonly occur in the setting of trauma, underlying structural heart disease, malignancy, and other immunocompromised states.

Pathophysiology

When introduced into healthy tissue, the HACEK group organisms have the potential for invasive disease and abscess formation. The pathogenesis of HACEK endocarditis is thought to be due to colonization of the oropharynx with bacteria that reach the vascular space following either trauma or local infection.

Haemophilus species are pleomorphic gram-negative coccobacilli that require X (hemin) and/or V (nicotinamide adenine dinucleotide) factors for isolation. These substances are found naturally in red blood cells. H parainfluenzae requires NAD (V factor) but not hemin (X factor), in contrast to H influenzae, which requires both. H parainfluenzae is capable of causing a variety of infections such as IE, otitis media, abscesses, and pneumonia, although it is an uncommon cause of these infections.[4] H influenzae on the other hand very rarely causes IE.

 Aggregatibacter actinomycetemcomitans with original genus name, "Actinobacillus," referred to the internal star shapes formed by colonies on solid media. In 2006, the genus was renamed Aggregatibacter, reflecting the propensity of organisms in this genus to grow as discrete clumps (aggregates) in broth culture. It can cause periodontal disease as well as IE. The ability of this organism to produce gingivitis is based in great part on its production of a leukotoxin and its ability to invade gingival cells. Cardiobacterium hominis is very rarely implicated in diseases other than endocarditis. C hominis is found in the oropharynx but rarely the gastrointestinal tract.[4]

Eikenella corrodens, as the name indicates, pits (or corrodes) into the surface of solid agar media. This pitting is associated with the presence of pilins, which may be important for adhesion to host tissue. It exudes a chlorine bleach odor. It is a member of the Neisseriaceae family, however can not be recovered on selective media for Neisseria spp such as Thayer-Martin agar. E corrodens can cause IE and is associated with infection following traumatic inoculation from the oral cavity and is found in up to 42% of abscesses from human bite wounds.[4]

Kingella kingae,also is a member of the Neisseriaceae but unlike Eikenella, it usually can be recovered on Thayer-Martin agar. In comparison to others in the HACEK group, K kingae is isolated from endocarditis infrequently. However, it is a significant cause of osteomyelitis/septic arthritis in children aged 6 months-3 years. The organism also may be transmitted person to person by respiratory droplets, and it caused a 2004 outbreak of septic arthritis in children attending daycare.[5]

 

Epidemiology

Frequency

Infective endocarditis is a rare disease with an annual incidence of 3 to 10 cases per 100,000 people.[6] The most common IE pathogens in children are gram-positive cocci, especially virulence group α-hemolytic streptococci, staphylococci and enterococci. The HACEK group are responsible for 1-3% of all infective endocarditis.[7] HACEK endocarditis mostly affects patients with underlying heart disease or prosthetic valves, and is characterized by an insidious course, with a mean diagnosis delay of 1 month (Haemophilus spp) to 3 months (Aggregatibacter and Cardiobacterium spp).

In Olmsted County, Minnesota, about 0.14 of every 100,000 people develop HACEK endocarditis each year. Twelvcases occurred in patients with prosthetic valve, and 33 cases occurred and in patients with native valve.[8]

In a prospective multinational cohort study from 64 hospitals in 28 countries, HACEK organisms were isolated in approximately 1.4% of infective endocarditis cases.[2]

For the most part, endocarditis is the focus of incidence studies of HACEK infections, but other infections can be caused by these organisms. By the mid-1980s,132 cases of H aphrophilus infection had been reported: 55% endocarditis, 15% brain abscess, and the remainder sinusitis, meningitis, pneumonitis, bacteremia, and empyema.

Nineteen cases of Eikenella brain infections were reported through 1983.[9]

Mortality/Morbidity

Infective endocarditis (IE) caused by the HACEK organisms typically is subacute, with the exception of H parainfluenzae endocarditis, which may present more acutely.[10] At the time of presentation, large valvular vegetations are common. Embolization is common and results in significant morbidity.

Patients hospitalized with definite or possible infective endocarditis by the International Collaboration on Endocarditis Prospective Cohort Study in 64 hospitals from 28 countries were included and characteristics of patients with HACEK endocarditis (HE) were compared with IE due to other pathogens. Of 5591 patients enrolled, 77 (1.4%) had HE. HE was associated with a younger age (47 vs 61 years; p< 0.001), a higher prevalence of immunologic/vascular manifestations (32% vs 20%; p< 0.008) and stroke (25% vs 17% p=0.05) but a lower prevalence of congestive heart failure (15% vs 30%; p=0.004), death in-hospital (4% vs 18%; p=0.001) or after 1 year follow-up (6% vs 20%; p=0.01) than IE due to other pathogens (n=5514). On multivariable analysis, stroke was associated with mitral valve vegetations (OR 3.60; CI 1.34–9.65; p< 0.01) and younger age (OR 0.62; CI 0.49–0.90; p< 0.01). The overall outcome of HE was excellent with the in-hospital mortality (4%) significantly better than for non-HE (18%; p< 0.001). Prosthetic valve endocarditis was more common in HE (35%) than non-HE (24%).[11]  

Mortality rates range from 10-40% and may vary by organism. Contemporary case series have suggested a modern mortality risk closer to 10-15%.[8]

The morbidity of IE caused by the HACEK group is similar to that of other types of endocarditis and includes embolization, local extension into the perivalvular area, congestive heart failure (CHF), and regurgitant valve lesions. Compared with all causes of IE, these organisms may be associated with an increased risk of embolization.[12]

Race

No racial differences have been reported in endocarditis caused by the HACEK organisms.

Sex

Older data suggest that HACEK endocarditis has a male predominance. However, there is not enough data available to say that, in the modern era, there is a predilection toward either sex.[13]

Age

The great majority of IE cases caused by HACEK organisms have been reported in older adults. HACEK IE in children with congenital heart disease has been reported.

In children, 70% of Kingella infections involve the skeletal system, predominantly septic arthritis. In a study of K kingae infections in children from southern Israel, Yagupsky and Dagan found that 45% of affected children were aged 13-24 months, with an attack rate of 27 cases per 100,000 children younger than 24 months. Almost 90% of all children with invasive K kingae infections have been younger than 5 years.[14]

Actinobacillus is highly associated with dental disease, being found in 50% of adults with periodontitis and 97% of children with juvenile periodontal disease. In a series of 57 cases of A actinomycetemcomitans endocarditis, poor dentition (46%) and abnormal cardiac valves (60%) were found to be predisposing factors.[15]

Prognosis

The prognosis is variable depending on many factors, such as delay in diagnosis, age of the patient, and occurrence of complications. Patients with uncomplicated IE caused by HACEK organisms generally respond well to therapy and have an excellent prognosis.[8]

History

Most cases of infective endocarditis (IE) caused by the HACEK organisms are subacute. Patients present with progressive symptoms developing over weeks. Some cases have been present for as long as 18 months before the correct diagnosis is made.[13] This delay often is due to failure to use special culture techniques.[16] (See Lab studies.) HACEK IE should be considered in the differential diagnoses of fever of unknown origin.

Fever is common, but may be absent in elderly individuals, immunocompromised patients, or patients taking anti-inflammatory drugs. In some series, fever was present in only 50% of cases.[13]

Nonspecific symptoms, such as weight loss, anorexia, nausea and vomiting, fatigue, back pain, and night sweats, are common. Symptoms may be insidious and may lead to a delay in diagnosis.

Patients may have a history of prior valvular disease.

A history of prior dental, urologic, and other procedures should be elicited.

A history of intravenous drug abuse should be elicited.

A sentinel headache may indicate the impending rupture of a mycotic aneurysm (MA). Typically MAs are multiple, distal, and fusiform aneurysms, but the angiographic and clinical presentations can vary widely. The most common presentation of MA is intracranial bleed.[17] Mycotic aneurysm can be intra or extra cranial.

Brain abscess can manifest as neurologic symptoms, such as focal weakness or numbness, cranial nerve dysfunction, and/or seizure. Primary brain abscess cases have been associated with canine saliva contamination or head and neck wounds.[9, 18]

Human bite or clenched fist injuries can be infected with HACEK organisms and can present as wound and deeper-tissue infections.

Various other presentations, including orbital cellulitis, necrotizing pneumonia, visceral abscess, bacteremia, and thrombophlebitis, have been reported.

Physical

The diagnosis of endocarditis is challenging. The physical findings are often subtle and difficult to identify for many clinicians. Special care should be taken to perform a comprehensive physical examination looking for evidence of endocarditis. Some of the areas to focus on are noted below.[19, 20, 21]

Heart

A new or changing heart murmur is the most consistent physical finding, but it may be absent, especially in right-sided endocarditis.

Peripheral

Because of the increased use of healthcare and diagnostic imaging, the peripheral manifestations of endocarditis are not seen as commonly as they once were.

Examine the patient for clubbing (with or without hypertrophic osteoarthropathy), splinter hemorrhages, mucocutaneous petechiae, Osler nodes, Janeway lesions, and Roth spots.

Splenomegaly can be present.

Embolic complications [22]

A vegetation can embolize to virtually any vessel and can result in various sequelae.

Observe for compromise of circulation to the limbs due to embolization.

Emboli to the central nervous system often presents as a focal neurological deficit or a stroke. Emboli to the frontal lobe may be more subtle, causing personality changes or loss of inhibition.[17]

Emboli to the kidney may cause flank tenderness, hematuria, and/or oliguria.

Embolization to heart vessels can have various manifestations, including acute myocardial infarction and arrhythmia.

A large mesenteric embolus can cause bowel ischemia and thus manifest as abdominal pain and tenderness.

A right-sided vegetation can embolize to the lung and present similarly to a septic pulmonary embolus or focal pneumonia.

Bone and joint foci can present as osteomyelitis and/or septic arthritis, manifesting as bone or joint tenderness, swelling, or nonhealing wound.

Other clinical manifestations

Other clinical manifestations, such as dental infection, skin and soft tissue infection/abscess, pneumonia/empyema, parotitis, eye infection, and sinus infection, require examination of the involved area, a thorough history, and assessment for underlying comorbidities.

Causes

Patients may have a history of a preceding dental, urologic, or gastroenterologic procedure.[22]

Periodontal disease is a known predisposing factor.

A history of intravenous drug use also should be considered because many drug users clean their needles or venipuncture sites with saliva. Among the HACEK organisms, E corrodens is the bacterium that has been most frequently associated with intravenous drug abuse.[23]

A history of heart valve abnormalities or the presence of a prosthetic heart valve or pacemaker device also predisposes to endocarditis.

A review of literature from Mayo Clinic between 1971 and 1976 identified predisposing factors such as trauma with wound infections, malignancies with abscesses, and congenital heart disease with endocarditis.[24]

Rare case reports have linked wound contamination with canine saliva and subsequent invasive infections, particularly of the head and neck, leading to brain abscess.[18, 25]

Complications

Many complications can result from IE, regardless of the causative organisms.

CHF is the complication of IE that has the greatest impact on prognosis. It may develop acutely from perforation of a valve leaflet, rupture of an infected chordae, valve obstruction, or because of sudden intracardiac shunts from fistulous tracts. When it appears more insidiously, CHF usually develops during the first month of therapy. Any deterioration in heart function should be taken very seriously because operative mortality increases dramatically after frank ventricular decompensation.

Neurologic complications, whether from emboli, abscess, hemorrhage, or arteritis, are the most frequent causes of death in patients with IE. Mycotic aneurysms usually are clinically silent until they rupture. Consider performing a magnetic resonance angiogram or cerebral CT scan to look for aneurysm in patients with subacute IE.

Splenic infarctions can occur in more than one third of patients but often are clinically silent.

Septic or bland emboli may reach the lung in right-sided endocarditis. These may cause pulmonary infarction, pneumonia, and empyema.

Laboratory Studies

When a HACEK organism is suspected, consider consulting a microbiologist so that special attention can be given to the blood culture specimen. Special procedures performed in the microbiology laboratory may improve the chances of isolating the organisms.[16]

Although prolonged incubation commonly is recommended in this setting, current research suggests it is the special laboratory procedures, rather than the time of incubation, that matter most.[16]

HACEK organisms can be isolated on routinely used non-selective media, often growing better on chocolate agar than on blood agar. They cannot be isolated from selective media designed for enterics such as MacConkey agar. Identification can be performed by automated systems but performance may be suboptimal. As with many other organisms, MALDI-TOF is emerging as a potential identification technology for the HACEK group.[4]

Molecular techniques for the detection and identification of microorganisms have been increasingly used for diagnostics in clinical microbiology. Polymerase chain reaction (PCR) of the 16S rRNA genes and sequencing has increased diagnostic yield, although diagnostic sensitivity is difficult to be determined at this time.[26]

Complete cell count may show anemia with or without reactive thrombocytosis. Total white cell count may or may not be increased.

Other inflammatory parameters should include erythrocyte sedimentation rate and C-reactive protein, although these are nonspecific.

Imaging Studies

Echocardiography

Echocardiography (TTE) plays a key role for the diagnosis of IE and must be performed as soon as IE is suspected. It allows to identify vegetation, abscess, new dehiscence of prosthetic valve, and assesses the number, size, shape, location, echogenicity, and mobility of vegetations so it also useful for prediction embolic risk. Transesophageal echocardiography (TEE) is indicated when TTE is positive or non diagnostic, in case of suspected complications, and when intracardiac device leads are present.[27]  

HACEK group organisms typically produce vegetations that are larger than vegetations found in IE due to other organisms, probably because of the longer mean time to diagnosis.

In addition to its diagnostic utility, echocardiography may play a prognostic role. Certain vegetation characteristics are associated with increased risk for embolism and mortality.[28]

The new guidelines propose new diagnostic criteria that consider the potentiality on integrated multimodality imaging so according to this new definitions include: (1) the identification of paravalvular lesions by cardiac computed tomography (CT) as a major criterion; (2) in the setting of the suspected endocarditis on a prosthetic valve, abnormal activity around the site of implantation detected by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT (only if the prosthesis was implanted for >3 months) or radiolabeled leukocyte single-photon emission CT (SPECT)/CT as a major criterion; and (3) the identification of recent embolic events or infectious aneurysms by imaging only (silent events) as a minor criterion.[27, 29]

CT scanning

Computed tomography (CT) scanning can be used for diagnosis of soft-tissue or visceral abscess.

MRI

Magnetic resonance imaging (RI) is more sensitive and specific for bone infection.

Procedures

The most common presentation of HACEK endocarditis is an indolent or subacute endocarditis that is cured with an appropriate course of intravenous antibiotics. In cases of less-common acute clinical presentation with perivalvular abscess and rapid hemodynamic deterioration with heart failure, valve replacement may be necessary.[30]

An arterial embolectomy for large emboli may be needed to salvage a limb or viscera.

Surgical interventions such as incision and drainage or abscess evacuation may be needed if clinically prompted.

Histologic Findings

The valvular lesions and vegetations of HACEK IE are very similar to those found in other types of subacute endocarditis, except that the larger size of the vegetations resembles those seen in fungal or staphylococcal disease.[31, 32]

Medical Care

Appropriate antibiotic therapy is key to the management of infective endocarditis (IE) caused by the HACEK organisms (see Medications). The Infectious Disease Society of America (IDSA) recommends the following[33] :

Antibiotic therapy may be fine-tuned when susceptibility data for the causative organism are available.[34]

Complications that arise (eg, heart failure, embolic complications) also require supportive medical therapy.

When treating a clenched fist injury or bite wound infection, HACEK organisms should be kept in consideration. E corrodens is resistant to macrolides, clindamycin, and metronidazole. H aphrophilus is also typically resistant to clindamycin.

Surgical Care

The decision to consider surgical therapy in patients with IE often is challenging and must be made on an individual basis. The following are several accepted indications for surgery in IE[12] :

Consultations

Treatment of HACEK endocarditis requires a multidisciplinary approach.

Consultation with an infectious disease specialist may be helpful for selecting antibiotics, monitoring therapy, and selecting the duration of therapy.

Consultation with a cardiologist may be helpful, especially if transesophageal echocardiography is needed or if CHF develops.

Management of large vegetations or mechanical complications warrants a cardiovascular surgeon's advice.

Consultation with a dentist is indicated if periodontal disease is present.

Surgery consult is prompted for abscess drainage.

Diet

No special diet is necessary in patients with HACEK group infections.

Activity

Although there is no evidence-based recommendation for activity levels in patients with endocarditis, it is prudent to keep activity light in the initial phase of treatment.

Prevention

The risk for endocarditis due to HACEK organisms may be reduced by maintenance of good dental hygiene.

Guidelines for infective endocarditis (IE) prophylaxis prior to dental procedures were updated in 2007. Current recommendations support the use of prophylactic antibiotics for high-risk lesions only.

Antibiotic prophylaxis should be considered before oral/dental procedures in patients with high-risk cardiac conditions.[36]

High-risk conditions include the following:

Long-Term Monitoring

Relapse may occur during the first 6 months following the end of treatment. Patients should be counseled and observed regarding relapse.

Further Inpatient Care

Careful clinical observation is the most important aspect of monitoring adequacy of therapy in HACEK group infections. Persistent or recurrent fever may be a sign of treatment failure, but it also may be due to hypersensitivity reactions, thrombophlebitis, or sterile embolization. Observe patients closely for signs of complications, such as embolic events or CHF.

Repeat blood cultures every 48 hours until they become negative.

Fever that lasts longer than 10 days after starting appropriate antibiotics should cause concern.

Causes of persistent fever include drug fever, antibiotic resistance, myocardial or septal abscesses, large vegetations that are difficult to sterilize, and metastatic infection (intracerebral mycotic aneurysms).

Inpatient & Outpatient Medications

In general, the entire course should be with intravenous antibiotics. Once the patient is stable and cultures are negative, completing intravenous therapy on an outpatient basis is reasonable. However, even in the outpatient setting, frequent evaluations are necessary to assess for response to therapy and for drug toxicity.

Although little evidence exists to support its use in this setting, ciprofloxacin could be used in oral form in certain circumstances. However, given the lack of evidence, this be reserved for special circumstances and in consultation with an infectious disease specialist.[12]

Transfer

If HACEK infection is diagnosed early, managing the infection in a center that does not offer cardiovascular surgery services may be possible. However, consider transfer to a health center with complete cardiac and neurological care for any patient at high risk for complications.

If the patient is stable, has good social support, and is afebrile with negative blood cultures, outpatient therapy can then be offered for the remainder of the treatment course.

Medication Summary

Empiric therapy with ceftriaxone or ampicillin-sulbactam is the recommended approach. Fluoroquinolones can be used in the case of allergy or intolerance to the recommended regimen. Treatment duration is 4 weeks for native valve disease and 6 weeks for prosthetic valve disease.

Ceftriaxone (Rocephin)

Clinical Context:  Drug of choice for treatment of endocarditis due to HACEK organisms. Third-generation cephalosporin with broad-spectrum, gram-negative activity. Arrests bacterial growth by binding to one or more penicillin-binding proteins. Recommended dose 2 gm q24 hrs IV. No adjustment necessary in persons with renal or hepatic impairment. Dose should be administered postdialysis if undergoing hemodialysis.

Ampicillin and sulbactam (Unasyn)

Clinical Context:  Drug combination of beta-lactamase inhibitor with ampicillin. Interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication orally.

Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens.

Ciprofloxacin (Cipro)

Clinical Context:  Alternative to ceftriaxone when treating HACEK in patients who are unable to tolerate beta-lactam treatment. Inhibits bacterial DNA synthesis and, consequently, growth. Recommended dose for HACEK Infective endocarditis is 1000 mg/24 h orally or 800 mg/24 h IV in 2 equally divided doses. Consider dose adjustment based on renal function.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Author

Zartash Zafar Khan, MD, FACP, Infectious Disease Consultant

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Pranatharthi Haran Chandrasekar, MBBS, MD, Professor, Chief of Infectious Disease, Department of Internal Medicine, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Christian P Sinave, MD, Associate Professor, Department of Medical Microbiology and Infectious Diseases, University of Sherbrooke Faculty of Medicine, Canada

Disclosure: Nothing to disclose.

Isaac P Humphrey, MD, Assistant Professor of Internal Medicine, Uniformed Services University of the Health Sciences; Clinical Assistant Professor of Internal Medicine, Wright State University Boonshoft School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Kenneth C Earhart, MD Deputy Head, Disease Surveillance Program, United States Naval Medical Research Unit #3

Kenneth C Earhart, MD is a member of the following medical societies: American College of Physicians, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and Undersea and Hyperbaric Medical Society

Disclosure: Nothing to disclose.

Barnett Gibbs, MD Assistant Chief, Department of Clinical Trials, Walter Reed Army Institute of Research, Infectious Disease Service, National Capital Consortium; Assistant Professor of Medicine, Uniformed Services University of the Health Sciences

Disclosure: Nothing to disclose.

Mirabelle Kelly, MD Fellow, Department of Microbiology and Infectious Disease, University of Sherbrooke, Canada

Mirabelle Kelly, MD is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

References

  1. Khaledi M, Sameni F, Afkhami H, Hemmati J, Asareh Zadegan Dezfuli A, Sanae MJ, et al. Infective endocarditis by HACEK: a review. J Cardiothorac Surg. 2022 Aug 19. 17 (1):185. [View Abstract]
  2. Chambers et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One. 2013. 8 (5):e63181. [View Abstract]
  3. Maia A, Goldstein FW, Acar JF, Roland F. Isolation of Eikenella corrodens from human infections: report of six cases. J Infect. 1980 Dec. 2 (4):347-53. [View Abstract]
  4. Who Are the HACEK Organisms?. American Society For Microbiology.
  5. Kiang KM, Ogunmodede F, Juni BA, Boxrud DJ, Glennen A, Bartkus JM, et al. Outbreak of osteomyelitis/septic arthritis caused by Kingella kingae among child care center attendees. Pediatrics. 2005 Aug. 116 (2):e206-13. [View Abstract]
  6. Aaron W. Yallowitz, Lawrence C. Decker. Infectious Endocarditis. StatPearls Publishing; 2023 Jan. 2023 Apr 24. [View Abstract]
  7. Revest M, Egmann G, Cattoir V, Tattevin P. HACEK endocarditis: state-of-the-art. Expert Rev Anti Infect Ther. 2016. 14 (5):523-30. [View Abstract]
  8. Das M, Badley AD, Cockerill FR, Steckelberg JM, Wilson WR. Infective endocarditis caused by HACEK microorganisms. Annu Rev Med. 1997. 48:25-33. [View Abstract]
  9. Cheng AF, South JR, French GL. Eikenella corrodens as a cause of brain abscess. Scand J Infect Dis. 1988. 20 (6):667-71. [View Abstract]
  10. Darras-Joly C, Lortholary O, Mainardi JL, Etienne J, Guillevin L, Acar J. Haemophilus endocarditis: report of 42 cases in adults and review. Haemophilus Endocarditis Study Group. Clin Infect Dis. 1997 Jun. 24(6):1087-94. [View Abstract]
  11. Stephen T. Chambers et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One. 2013. 8 (5):e63181. [View Abstract]
  12. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005 Jun 14. 111(23):e394-434. [View Abstract]
  13. Geraci JE, Wilson WR. Symposium on infective endocarditis. III. Endocarditis due to gram- negative bacteria. Report of 56 cases. Mayo Clin Proc. 1982 Mar. 57(3):145-8. [View Abstract]
  14. Yagupsky P, Dagan R. Kingella kingae: an emerging cause of invasive infections in young children. Clin Infect Dis. 1997 May. 24 (5):860-6. [View Abstract]
  15. Tleyjeh IM, Steckelberg JM, Murad HS, Anavekar NS, Ghomrawi HM, Mirzoyev Z, et al. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. JAMA. 2005 Jun 22. 293 (24):3022-8. [View Abstract]
  16. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis. 2005 Dec 1. 41(11):1677-80. [View Abstract]
  17. Kannoth S, Thomas SV. Intracranial microbial aneurysm (infectious aneurysm): current options for diagnosis and management. Neurocrit Care. 2009. 11(1):120-9. [View Abstract]
  18. FAGER CA. An unusual brain abscess: report of a case. Lahey Clin Bull. 1961 Apr-Jun. 12:108-12. [View Abstract]
  19. Paterick TE, Paterick TJ, Nishimura RA, Steckelberg JM. Complexity and subtlety of infective endocarditis. Mayo Clin Proc. 2007 May. 82(5):615-21. [View Abstract]
  20. Yew HS, Chambers ST, Roberts SA, Holland DJ, Julian KA, Raymond NJ, et al. Association between HACEK bacteraemia and endocarditis. J Med Microbiol. 2014 Jun. 63:892-5. [View Abstract]
  21. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One. 2013. 8(5):e63181. [View Abstract]
  22. Malani AN, Aronoff DM, Bradley SF, Kauffman CA. Cardiobacterium hominis endocarditis: Two cases and a review of the literature. Eur J Clin Microbiol Infect Dis. 2006 Sep. 25(9):587-95. [View Abstract]
  23. Miró JM, del Río A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect Dis Clin North Am. 2002 Jun. 16(2):273-95, vii-viii. [View Abstract]
  24. Bieger RC, Brewer NS, Washington JA 2nd. Haemophilus aphrophilus: a microbiologic and clinical review and report of 42 cases. Medicine (Baltimore). 1978 Jul. 57 (4):345-55. [View Abstract]
  25. Abla AA, Maroon JC, Slifkin M. Brain abscess due to Haemophilus aphrophilus: possible canine transmission. Neurosurgery. 1986 Jul. 19 (1):123-4. [View Abstract]
  26. Lisby G, Gutschik E, Durack DT. Molecular methods for diagnosis of infective endocarditis. Infect Dis Clin North Am. 2002 Jun. 16 (2):393-412, x. [View Abstract]
  27. Sordelli C, Fele N, Mocerino R, Weisz SH, Ascione L, Caso P, et al. Infective Endocarditis: Echocardiographic Imaging and New Imaging Modalities. J Cardiovasc Echogr. 2019 Oct-Dec. 29 (4):149-155. [View Abstract]
  28. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation. 2005 Jul 5. 112(1):69-75. [View Abstract]
  29. Gilbert Habib et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21. 36 (44):3075-3128. [View Abstract]
  30. Patrick WD, Brown WD, Ian Bowmer M, Sinave CP. Infective endocarditis due to Eikenella corrodens: Case report and review of the literature. Can J Infect Dis. 1990 Winter. 1 (4):139-42. [View Abstract]
  31. Trexler Hessen M, Abrutyn E. Gram-Negative Bacterial Endocarditis. Kaye D, ed. Infective Endocarditis. 2nd ed. New York, NY: Raven Press; 1992. 251-64.
  32. Yamamoto S, Hosokawa N, Sogi M, Inakaku M, Imoto K, Ohji G, et al. Impact of infectious diseases service consultation on diagnosis of infective endocarditis. Scand J Infect Dis. 2011 Dec 18. [View Abstract]
  33. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015 Oct 13. 132 (15):1435-86. [View Abstract]
  34. Coburn B, Toye B, Rawte P, Jamieson FB, Farrell DJ, Patel SN. Antimicrobial susceptibilities of clinical isolates of HACEK organisms. Antimicrob Agents Chemother. 2013 Apr. 57(4):1989-91. [View Abstract]
  35. Evans CF, Gammie JS. Surgical management of mitral valve infective endocarditis. Semin Thorac Cardiovasc Surg. 2011 Autumn. 23(3):232-40. [View Abstract]
  36. [Guideline] Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 9. 116(15):1736-54. [View Abstract]
  37. Geraci JE, Wilson WR. Symposium on infective endocarditis. III. Endocarditis due to gram-negative bacteria. Report of 56 cases. Mayo Clin Proc. 1982 Mar. 57 (3):145-8. [View Abstract]
  38. Christou L, Economou G, Zikou AK, Saplaoura K, Argyropoulou MI, Tsianos EV. Acute Haemophilus parainfluenzae endocarditis: a case report. J Med Case Rep. 2009 Jul 16. 3:7494. [View Abstract]
  39. Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med. 2007 Dec 18. 147(12):829-35. [View Abstract]
  40. Ferreiros E, Nacinovich F, Casabé JH, Modenesi JC, Swieszkowski S, Cortes C, et al. Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina-2 (EIRA-2) Study. Am Heart J. 2006 Feb. 151(2):545-52. [View Abstract]
  41. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis. 2005 Dec 1. 41(11):1677-80. [View Abstract]
  42. Bayer AS, Scheld WM. Endocarditis and intravascular infections. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000. 857-902.
  43. Berbari EF, Cockerill FR, Steckelberg JM. Infective endocarditis due to unusual or fastidious microorganisms. Mayo Clin Proc. 1997 Jun. 72(6):532-42. [View Abstract]
  44. Goutzmanis JJ, Gonis G, Gilbert GL. Kingella kingae infection in children: ten cases and a review of the literature. Pediatr Infect Dis J. 1991 Sep. 10(9):677-83. [View Abstract]
  45. [Guideline] Gustke CJ. A review of localized juvenile periodontitis (LJP): II. Clinical trials and treatment guidelines. Gen Dent. 1998 Nov-Dec. 46(6):580-7; quiz 588-9. [View Abstract]
  46. Gustke CJ. A review of localized juvenile periodontitis (LJP): Part I. Clinical features, epidemiology, etiology, and pathogenesis. Gen Dent. 1998 Sep-Oct. 46(5):491-7. [View Abstract]
  47. Lampe AS, Schroijen MA, Smith SJ. [Endocarditis due to Aggregatibacter (formerly: Actinobacillus) actinomycetemcomitans, a bacterium that grows in characteristic star-shaped colonies]. Ned Tijdschr Geneeskd. 2008 Apr 5. 152(14):827-30. [View Abstract]
  48. Parker SW, Apicella MA, Fuller CM. Hemophilus endocarditis. Two patients with complications. Arch Intern Med. 1983 Jan. 143(1):48-51. [View Abstract]
  49. Pereira RM, Bucaretchi F, Tresoldi AT. Infective endocarditis due to Haemophilus aphrophilus: a case report. J Pediatr (Rio J). 2008 Mar-Apr. 84(2):178-80. [View Abstract]
  50. Weinstein L, Brusch JL. Gram-Negative and Other Organisms. Weinstein L, Brusch JL, eds. Infective Endocarditis. New York, NY: Oxford University Press; 1996. 73-122.
  51. Westling K, Vondracek M. Actinobacillus (Aggregatibacter) actinomycetemcomitans (HACEK) identified by PCR/16S rRNA sequence analysis from the heart valve in a patient with blood culture negative endocarditis. Scand J Infect Dis. 2008. 40(11-12):981-3. [View Abstract]
  52. Kaplan AH, Weber DJ, Oddone EZ, Perfect JR. Infection due to Actinobacillus actinomycetemcomitans: 15 cases and review. Rev Infect Dis. 1989 Jan-Feb. 11 (1):46-63. [View Abstract]
  53. Lowenthal A, Weisblum-Neuman H, Birk E, Ashkenazi-Hoffnung L, Levy I, Ben-Zvi H, et al. Clinical Features and Comparison of Kingella and Non-Kingella Endocarditis in Children, Israel. Emerg Infect Dis. 2021 Mar. 27 (3):703-709. [View Abstract]